22:30:36 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2022-10-06 12:15:00

Professor Morten Meldal was yesterday awarded the Nobel Prize in Chemistry. Morten and 2cureX’s two founders, Ole Thastrup and Grith Hagel, collaborated at the Carlsberg Research Center and together invented the core technologies that were the basis for establishing 2cureX.

2cureX was spun-out of Carlsberg in 2006 with these patents that described how patient cells and drugs could be immobilized on solid support and tested for drug sensitivity. The patents have been granted in full in global territories. These initial patents created the basis for subsequent discoveries and issuance of additional intellectual property (IP), and thereby established the comprehensive and strong IP portfolio that protects the IndiTreat® technology today.

Ole Thastrup, CSO & Founder of 2cureX “I would like to take the opportunity to congratulate Morten Meldal on this fantastic achievement. Morten is one of the most dedicated and innovative scientists I have met. He has a unique ability to conduct groundbreaking research and look for innovative applications. It has been an honor to work closely with Morten and to see how our early ideas and associated patents created the original basis for 2cureX”.

2cureX continues to roll out its drug sensitivity tests under the CE-IVD-marked IndiTreat® family. Now present in 17 countries in Europe and the near East, the company aims to change the way in which patients with metastatic colorectal cancer are treated. IndiTreat® provides unique supplementary information related to a patient’s sensitivity to chemotherapy, and so delivers guidance to the oncologist’s treatment decision.